Capstone Investment Advisors’s Corcept Therapeutics CORT Stock Holding History

Capstone Investment Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$237K	Buy	+2,726	New	+$165K	﹤0.01%	1555
2025 Q3	–	Sell	-5,476	Closed	-$402K	–	1929
2025 Q2	$402K	Buy	+5,476	New	+$397K	﹤0.01%	1244
2025 Q1	–	Sell	-8,862	Closed	-$447K	–	1444
2024 Q4	$447K	Sell	8,862 -9,964	-53%	-$522K	﹤0.01%	1346
2024 Q3	$871K	Buy	+18,826	New	+$669K	﹤0.01%	1001
2023 Q4	–	Sell	-7,367	Closed	-$201K	–	2150
2023 Q3	$201K	Buy	+7,367	New	+$213K	﹤0.01%	1811
2017 Q1	–	Sell	-29,000	Closed	-$210K	–	918
2016 Q4	$210K	Buy	+29,000	New	+$227K	0.01%	811

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capstone Investment Advisors's CORT Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,726 shares worth $237K. The stake represents ﹤0.01% of the portfolio and ranks #1555 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in CORT as recently as Q2 2025.

Capstone Investment Advisors first reported a position in CORT in Q4 2016 and has held it in 6 quarters since. The position peaked at $871K in Q3 2024. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Capstone Investment Advisors held 2,726 shares of Corcept Therapeutics worth $237K as of Q2 2026.
Corcept Therapeutics was a new Capstone Investment Advisors position in Q2 2026.
Corcept Therapeutics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1555 holding.
Capstone Investment Advisors first reported a position in Corcept Therapeutics in Q4 2016 and has held it in 6 quarters since.
Capstone Investment Advisors's Corcept Therapeutics position peaked at $871K in Q3 2024.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.